Therapeutic antibody research

Monoclonal antibodies for immunotherapy in cancer are a treatment that aids the body’s own immune system to attack tumor cells. In the last 20 years, monoclonal antibody–based treatment for cancer has proven one of the most effective therapeutic strategies for solid tumors, as well as tumors of hematopoietic and lymphoid tissues. Therapeutic antibodies against cancer are used and designed to target cancer surface antigens or to unlock checkpoint inhibitors. This way, the immune response of the human body is initiated to fight tumor cells.

Therapeutic antibody research usually starts with identification and validation of novel targets for immunotherapy.  
For subsequent discovery of antibody candidates, B cells are sorted or separated using magnetic beads. The B cells are used either for sequencing of B cell receptors (BCRs) or B cell cultivation and binder selection using the cell culture supernatant.  
The final step, antibody functionality, needs to be verified in cell-based assays to determine the mode of action and effector function. Often, additional optimization of antibody candidates and further functionality testing is performed to improve specificity (affinity and avidity), safety (cytokine release, immunogenicity testing), and efficacy (combination therapies, antibody format selection).   

Our goal is it to support you at every step of your workflow, to simplify your research, and ensure reproducibility in your data.  
 

Our therapeutic antibody discovery research solutions support: 

Target identification: 

• Deep phenotyping of the tumor microenvironment by ultra high content imaging with the MACSima™ Imaging Platform

Antibody discovery: 

• Separation of your B cell subset of interest using MACS® Technology
• Gentle sorting of viable B cells with the MACSQuant® Tyto® Cell Sorter and REAlease® Antibodies
• Reliable activation and expansion of primary B cells using the B Cell Expansion Kit, human

Functionality testing: 

• Reproducible functionality screenings, as well as quality controls (QC), for assay read-out, e.g., by flow cytometric surface marker analysis or cytokine profiling
• We can support you with any kind of cell-based assay including antibody-dependent cellular cytotoxicity (ADCC) assay, mixed lymphocyte reaction (MLR), complement-dependent cytotoxicity assays (CDC), immunogenicity screenings, proliferation, differentiation, activation, and killing assays, cytokine secretion assays, MDSC suppression assays, and many more …